Can a Dual-Drug combo shrink lung tumors before surgery?

NCT ID NCT06743581

NEW Recruiting now Disease control Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial is testing whether combining two immunotherapy drugs, cemiplimab and dupilumab, can safely and effectively shrink tumors in people with early-stage, operable non-small cell lung cancer. Participants receive both drugs before their scheduled surgery, and researchers will measure how much of the tumor is destroyed at the time of removal. The study also monitors safety, side effects, and long-term outcomes like survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cemiplimab and dupilumab
What this could lead to: If successful, this combination could improve the chance of eliminating tumors before surgery, potentially leading to better long-term outcomes for people with early-stage lung cancer.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. The combination may cause side effects, and the added benefit of dupilumab is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOTHERAPY NEOADJUVANT THERAPY NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

CHUM
RECRUITING

Montreal, Quebec, H2X 0A9, Canada
Centre hospitalier de l'Université de Montréal (CHUM)
NOT_YET_RECRUITING

Montreal, Quebec, H2X 3E4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.